Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. and China. Concurrently, the ...
This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results